ImmuCell (FRA:IUL) Tariff Resilience Score: 4/10 (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IUL ImmuCell Corp FRA:IUL
58 GF Score
Price €8.30
GF Value €5.66
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is ImmuCell Tariff Resilience Score?

ImmuCell FRA:IUL +1.22% 58 Tariff Resilience Score is 4 as of Aug. 20, 2026. GuruFocus rates FRA:IUL with a GF Score™ of 58/100 and a GF Value™ of €5.66 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,362 Biotechnology companies, ImmuCell ranks better than 52.72% on this metric.

ImmuCell has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

ImmuCell has ImmuCell Corp is exposed to tariffs due to its reliance on imported raw materials. The company has limited pricing power and has been affected by past tariff changes. It is exploring alternative suppliers but remains vulnerable in the short term.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes ImmuCell might have Average Resilient.

ImmuCell  (FRA:IUL) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

ImmuCell Tariff Resilience Score Related Terms

FRA:IUL vs COYA, ENTX, BDTX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, ImmuCell's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuCell Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where ImmuCell's Tariff Resilience Score falls into.


FRA:IUL
58GF Score
ImmuCell Corp FRA:IUL
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
ImmuCell (FRA:IUL) has a Tariff Resilience Score of 4 as of Aug. 20, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, ImmuCell ranks #644 out of 1362 companies in the Biotechnology industry, placing it in the top 47.3%.
Is ImmuCell's Tariff Resilience Score too high?
ImmuCell's current Tariff Resilience Score is 4. The Biotechnology industry median Tariff Resilience Score is 4.00. ImmuCell's value of 4 is 0% at this industry median. Based on the distribution chart, ImmuCell ranks #644 out of 1362 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ImmuCell has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's Tariff Resilience Score compare to COYA and ENTX?
According to the Biotechnology industry distribution chart, ImmuCell ranks #644 out of 1362 companies for Tariff Resilience Score. This puts ImmuCell in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. ImmuCell's value of 4 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,362 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImmuCell's current Tariff Resilience Score of 4 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImmuCell's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (FRA:IUL) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.66, compared to a current price of €8.30 — trading 46.6% above its estimated fair value. The current Tariff Resilience Score is 4 and 0% at the Biotechnology industry median of 4.00. ImmuCell's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For ImmuCell (FRA:IUL), the current Tariff Resilience Score is 4 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmuCell (FRA:IUL) Overvalued in 2026?

Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued. The current stock price of €8.30 is trading 46.6% above its estimated GF Value™ of €5.66. GuruFocus considers ImmuCell to be Significantly Overvalued.

Key valuation signals for FRA:IUL:

  • Tariff Resilience Score: 4
  • GF Value™: €5.66 vs. price of €8.30 (46.6% above fair value)
  • GF Score™: 58/100 with 5 warning signs
  • Industry Position: 0% at the Biotechnology median (#644 of 1362)

No single metric tells the full story. See the FRA:IUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImmuCell Business Description

Other Exchanges ICCC:USA
Address 56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
58GF Score

Get the complete analysis for FRA:IUL

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.30
Price
€5.66
GF Value